Qyuns Therapeutics repurchases 70,000 H-shares; treasury stock rises to 2.71 million units

Bulletin Express05-28

Qyuns Therapeutics Co., Ltd. disclosed that on 28 May 2026 it bought back 70,000 H-shares on the Hong Kong Stock Exchange at prices ranging from HKD 16.21 to HKD 16.60 per share, for a total consideration of HKD 1.16 million. The volume-weighted average cost was HKD 16.52 per share.

Following the transaction, outstanding shares (excluding treasury stock) fell to 224.36 million, while treasury shares increased to 2.71 million. The company’s total issued share capital remains unchanged at 227.07 million shares, with the latest repurchase representing 0.03 % of the issued shares outstanding prior to the buyback.

The purchases were made under the general mandate approved on 20 June 2025, which authorises the company to repurchase up to 22.21 million shares. Including the latest operation, Qyuns Therapeutics has repurchased 2.71 million shares to date, equivalent to 1.22 % of the issued share count on the mandate’s approval date.

In accordance with Hong Kong Listing Rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 27 June 2026. The repurchased shares will be held as treasury stock; none have been cancelled as of the disclosure date.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1152568699?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-28 20:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152568699","market":"us","top_or_hot":-1,"title":"Qyuns Therapeutics repurchases 70,000 H-shares; treasury stock rises to 2.71 million units","media":"Bulletin Express","content":"<p>Qyuns Therapeutics Co., Ltd. disclosed that on 28 May 2026 it bought back 70,000 H-shares on the Hong Kong Stock Exchange at prices ranging from HKD 16.21 to HKD 16.60 per share, for a total consideration of HKD 1.16 million. The volume-weighted average cost was HKD 16.52 per share.</p>\n<p>Following the transaction, outstanding shares (excluding treasury stock) fell to 224.36 million, while treasury shares increased to 2.71 million. The company’s total issued share capital remains unchanged at 227.07 million shares, with the latest repurchase representing 0.03 % of the issued shares outstanding prior to the buyback.</p>\n<p>The purchases were made under the general mandate approved on 20 June 2025, which authorises the company to repurchase up to 22.21 million shares. Including the latest operation, Qyuns Therapeutics has repurchased 2.71 million shares to date, equivalent to 1.22 % of the issued share count on the mandate’s approval date.</p>\n<p>In accordance with Hong Kong Listing Rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 27 June 2026. The repurchased shares will be held as treasury stock; none have been cancelled as of the disclosure date.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qyuns Therapeutics repurchases 70,000 H-shares; treasury stock rises to 2.71 million units</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQyuns Therapeutics repurchases 70,000 H-shares; treasury stock rises to 2.71 million units\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-28 20:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Qyuns Therapeutics Co., Ltd. disclosed that on 28 May 2026 it bought back 70,000 H-shares on the Hong Kong Stock Exchange at prices ranging from HKD 16.21 to HKD 16.60 per share, for a total consideration of HKD 1.16 million. The volume-weighted average cost was HKD 16.52 per share.</p>\n<p>Following the transaction, outstanding shares (excluding treasury stock) fell to 224.36 million, while treasury shares increased to 2.71 million. The company’s total issued share capital remains unchanged at 227.07 million shares, with the latest repurchase representing 0.03 % of the issued shares outstanding prior to the buyback.</p>\n<p>The purchases were made under the general mandate approved on 20 June 2025, which authorises the company to repurchase up to 22.21 million shares. Including the latest operation, Qyuns Therapeutics has repurchased 2.71 million shares to date, equivalent to 1.22 % of the issued share count on the mandate’s approval date.</p>\n<p>In accordance with Hong Kong Listing Rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 27 June 2026. The repurchased shares will be held as treasury stock; none have been cancelled as of the disclosure date.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02509","symbol_name":"荃信生物-B","start_time":0,"source_url":"","article_id":"1152568699","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152568699","pubTimestamp":1779970965,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Qyuns Therapeutics Co., Ltd. disclosed that on 28 May 2026 it bought back 70,000 H-shares on the Hong Kong Stock Exchange at prices ranging from HKD 16.21 to HKD 16.60 per share, for a total...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02509":"荃信生物-B"},"translate_title":"Qyuns Therapeutics回购7万股H股；库存增至271万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":1},"content_text":"Qyuns Therapeutics Co., Ltd. disclosed that on 28 May 2026 it bought back 70,000 H-shares on the Hong Kong Stock Exchange at prices ranging from HKD 16.21 to HKD 16.60 per share, for a total consideration of HKD 1.16 million. The volume-weighted average cost was HKD 16.52 per share.\nFollowing the transaction, outstanding shares (excluding treasury stock) fell to 224.36 million, while treasury shares increased to 2.71 million. The company’s total issued share capital remains unchanged at 227.07 million shares, with the latest repurchase representing 0.03 % of the issued shares outstanding prior to the buyback.\nThe purchases were made under the general mandate approved on 20 June 2025, which authorises the company to repurchase up to 22.21 million shares. Including the latest operation, Qyuns Therapeutics has repurchased 2.71 million shares to date, equivalent to 1.22 % of the issued share count on the mandate’s approval date.\nIn accordance with Hong Kong Listing Rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 27 June 2026. The repurchased shares will be held as treasury stock; none have been cancelled as of the disclosure date.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1152568699","isCrawlerRequest":true}